Sign In
Buy CAI
$15.67
-0.420 (-2.61%)
At Close: Jul 31, 2026
Caris Life Sciences Reports Second Quarter 2025 Financial Results
04:05pm, Tuesday, 12'th Aug 2025
IRVING, Texas , Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results for the quarter
Groundbreaking study in Nature Communications highlights AI's role in transforming immunotherapy decisions and precision oncology IRVING, Texas , Aug. 6, 2025 /PRNewswire/ -- Caris Life Sciences® (
Caris GPSai™ utilizes deep learning to significantly improve diagnostic accuracy for cancers of unknown primary and misclassified tumors IRVING, Texas , Aug. 5, 2025 /PRNewswire/ -- Caris Life Scie
Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025
08:30am, Wednesday, 23'rd Jul 2025
IRVING, Texas , July 23, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it wi
Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis
08:30am, Tuesday, 22'nd Jul 2025
Validation was shared via a Letter to the Editor in the New England Journal of Medicine IRVING, Texas , July 22, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric,
Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. IRVING, Texas , July 8, 2025 /PRNew
U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million
04:20pm, Sunday, 22'nd Jun 2025
A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced this past week. One IPO is currently scheduled to list in the week ahead,
Caris Life Sciences: Momentum Returns In The IPO Market
02:51pm, Friday, 20'th Jun 2025
Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine, but remains deeply unprofitable despite narrowing losses. The IPO was strong, with shar
S&P 500 (NYSEARCA: SPY) Live: Markets Withstand Unrelenting Mideast Pressure, Rate Decision
11:00am, Thursday, 19'th Jun 2025
Live Updates Live Coverage Has Ended IPO Soars 12:56 pm by Gerelyn Terzo The markets embraced healthcare newcomer Caris Life Sciences (Nasdaq: CAI) today, marking its debut on the Nasdaq. After pricin
Live Nasdaq Composite: Markets Hold Steady on Fed Day as Mideast Tensions Boil
04:02pm, Wednesday, 18'th Jun 2025
Live Updates Live Coverage Updates appear automatically as they are published. Today's IPO Receives Warm Welcome 12:53 pm by Gerelyn Terzo The markets rolled out the welcome mat for healthcare st
Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut
04:01pm, Wednesday, 18'th Jun 2025
On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering.
This ‘AI TechBio' company goes public as IPO demand spreads to biotech
02:50pm, Wednesday, 18'th Jun 2025
Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company's business of molecular profiling and drug research using artificial intelligence.
Caris Life Sciences Shares Rise Following IPO
01:50pm, Wednesday, 18'th Jun 2025
The biotechnology company started trading at $27 each on Wednesday afternoon, a day after the company's IPO was priced at $21 a share. The stock was recently up 26% and trading at $26.48.
Sixth Street-backed Caris Life valued at $7.66 billion in strong Nasdaq debut
12:46pm, Wednesday, 18'th Jun 2025
Caris Life Sciences' shares jumped nearly 29% in their New York debut on Wednesday, fetching the cancer diagnostic firm a valuation of $7.66 billion and signaling a growing investor appetite for new l
Caris Life Sciences CEO on IPO debut, using AI to fight against cancer
07:39am, Wednesday, 18'th Jun 2025
David Dean Halbert, Caris Life Sciences chairman, founder and CEO, joins 'Squawk Box' to discuss the company's IPO debut, how the company uses AI technology to help diagnose and treat cancer,
